CSBio CSBio

X
[{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$74.0 million","upfrontCash":"Undisclosed","newsHeadline":"AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"AgomAb Therapeutics N.V"},{"orgOrder":0,"company":"Dualyx","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dualyx Raises 40 Million To Progress Treg Therapies For Autoimmune Diseases Into The Clinic","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Dualyx"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting the highly attractive TNF receptor 2 (TNFR2) and widely regarded as a master control switch in immune modulation, as well as its pipeline of Treg candidates.

            Lead Product(s): DT-001

            Therapeutic Area: Immunology Product Name: DT-001

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Fountain Healthcare Partners

            Deal Size: $44.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing May 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Proceeds to further advance lead compound AGMB-101 and expand pipeline in inflammatory, metabolic and fibrotic diseases.

            Lead Product(s): AGMB-101

            Therapeutic Area: Immunology Product Name: AGMB-101

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Redmile Group

            Deal Size: $74.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing March 10, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY